TRACON Pharmaceuticals (TCON) Scheduled to Post Earnings on Monday

TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) is scheduled to post its quarterly earnings results after the market closes on Monday, August 14th. Analysts expect TRACON Pharmaceuticals to post earnings of ($0.36) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) last announced its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.07). On average, analysts expect TRACON Pharmaceuticals to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Get TRACON Pharmaceuticals alerts:

TRACON Pharmaceuticals Price Performance

Shares of NASDAQ TCON opened at $0.32 on Friday. TRACON Pharmaceuticals has a 12-month low of $0.26 and a 12-month high of $2.32. The company has a market capitalization of $9.07 million, a PE ratio of -0.25 and a beta of 1.21. The firm’s 50-day moving average is $0.37 and its two-hundred day moving average is $1.03.

Hedge Funds Weigh In On TRACON Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Jane Street Group LLC acquired a new position in shares of TRACON Pharmaceuticals in the first quarter valued at approximately $27,000. Charles Schwab Investment Management Inc. acquired a new position in TRACON Pharmaceuticals during the first quarter worth approximately $43,000. Susquehanna International Group LLP acquired a new position in TRACON Pharmaceuticals during the first quarter worth approximately $79,000. Virtu Financial LLC acquired a new position in TRACON Pharmaceuticals during the fourth quarter worth approximately $67,000. Finally, Renaissance Technologies LLC increased its position in TRACON Pharmaceuticals by 80.1% during the second quarter. Renaissance Technologies LLC now owns 52,600 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 23,400 shares during the last quarter. Institutional investors and hedge funds own 49.80% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Maxim Group reduced their price target on shares of TRACON Pharmaceuticals from $8.00 to $3.00 in a report on Thursday, May 11th. StockNews.com started coverage on shares of TRACON Pharmaceuticals in a research report on Friday. They issued a “hold” rating for the company. Finally, Robert W. Baird cut their price objective on shares of TRACON Pharmaceuticals from $8.00 to $7.00 in a research report on Thursday, May 11th.

Check Out Our Latest Stock Report on TCON

About TRACON Pharmaceuticals

(Get Free Report)

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications.

Featured Stories

• Five stocks we like better than TRACON Pharmaceuticals
• 3 Small Caps With Big Return Potential
• Investing in Coffee: 3 Great Strategies to Consider
• Are Stock Buybacks Good for the Average Investor?
• 5 Best Stocks to Buy in a Bear Market
• How Investors Can Identify and Successfully Trade Gap-Up Stocks
• 3 Pharmaceutical Stocks to Buy and Hold for the Long Haul

Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.